Brazil Withdraws Threat To Produce Generic AIDS Drug

Article

RIO DE JANEIRO-The Brazilian government has reached a tentative deal with Swiss pharmaceutical giant Roche to purchase the generic version of the AIDS drug Nelfinavir.

The South American country announced last week it would begin producing the drug in state-owned laboratories for sale January 1, 2002 because a deal had not been reached with the company. Brazil is one of the only countries in the world to guarantee treatment for all AIDS patients, including a free-of-charge program. Nelfinavir is part of the drug cocktail offered by the government for patients in need. They provided the drug to some 90,000 patients last year alone.

The Brazilian minister of health said the government was glad to have reached a deal with Roche, which will now sell the drug at a 40% reduced rate. The government will pay $35 million each year for the drug and ensure the company continued patent protection.

The Brazilian government had previously agreed to purchase other AIDS pharmaceuticals with New Jersey-based Merck after the company reduced rates of two medications by 70%.

The deal between the Brazilian government and Roche comes after 6 months of negotiations.

Brazil has the highest rate of AIDS infection in Latin America, with 210,5000 people infected.

Information from www.washingtonpost.com

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.